Search

Your search keyword '"Baine, Michael J."' showing total 169 results
Start Over Author "Baine, Michael J."
169 results on '"Baine, Michael J."'

3. Heme Oxygenase-1 and Prostate Cancer: Function, Regulation, and Implication in Cancer Therapy.

Author

Salloom, Ramia J., Ahmad, Iman M., Sahtout, Dania Z., Baine, Michael J., and Abdalla, Maher Y.

Subjects
PROGNOSIS, THERAPEUTICS, TUMOR microenvironment, CANCER treatment, PROSTATE cancer
Abstract

Prostate cancer (PC) is a significant cause of mortality in men worldwide, hence the need for a comprehensive understanding of the molecular mechanisms underlying its progression and resistance to treatment. Heme oxygenase-1 (HO-1), an inducible enzyme involved in heme catabolism, has emerged as a critical player in cancer biology, including PC. This review explores the multifaceted role of HO-1 in PC, encompassing its function, regulation, and implications in cancer therapy. HO-1 influences cell proliferation, anti-apoptotic pathways, angiogenesis, and the tumor microenvironment, thereby influencing tumor growth and metastasis. HO-1 has also been associated with therapy resistance, affecting response to standard treatments. Moreover, HO-1 plays a significant role in immune modulation, affecting the tumor immune microenvironment and potentially influencing therapy outcomes. Understanding the intricate balance of HO-1 in PC is vital for developing effective therapeutic strategies. This review further explores the potential of targeting HO-1 as a therapeutic approach, highlighting challenges and opportunities. Additionally, clinical implications are discussed, focusing on the prognostic value of HO-1 expression and the development of novel combined therapies to augment PC sensitivity to standard treatment strategies. Ultimately, unraveling the complexities of HO-1 in PC biology will provide critical insights into personalized treatment approaches for PC patients. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

18. Supplementary Information from MUC4-Mediated Regulation of Acute Phase Protein Lipocalin 2 through HER2/AKT/NF-κB Signaling in Pancreatic Cancer

Author

Kaur, Sukhwinder, primary, Sharma, Neil, primary, Krishn, Shiv Ram, primary, Lakshmanan, Imay, primary, Rachagani, Satyanarayana, primary, Baine, Michael J., primary, Smith, Lynette M., primary, Lele, Subodh M., primary, Sasson, Aaron R., primary, Guha, Sushovan, primary, Mallya, Kavita, primary, Anderson, Judy M., primary, Hollingsworth, Michael A., primary, and Batra, Surinder K., primary

Published
2023
Full Text
View/download PDF

19. Supplementary Fig. 2 from MUC4-Mediated Regulation of Acute Phase Protein Lipocalin 2 through HER2/AKT/NF-κB Signaling in Pancreatic Cancer

Author

Kaur, Sukhwinder, primary, Sharma, Neil, primary, Krishn, Shiv Ram, primary, Lakshmanan, Imay, primary, Rachagani, Satyanarayana, primary, Baine, Michael J., primary, Smith, Lynette M., primary, Lele, Subodh M., primary, Sasson, Aaron R., primary, Guha, Sushovan, primary, Mallya, Kavita, primary, Anderson, Judy M., primary, Hollingsworth, Michael A., primary, and Batra, Surinder K., primary

Published
2023
Full Text
View/download PDF

20. Supplementary Fig. 3 from MUC4-Mediated Regulation of Acute Phase Protein Lipocalin 2 through HER2/AKT/NF-κB Signaling in Pancreatic Cancer

Author

Kaur, Sukhwinder, primary, Sharma, Neil, primary, Krishn, Shiv Ram, primary, Lakshmanan, Imay, primary, Rachagani, Satyanarayana, primary, Baine, Michael J., primary, Smith, Lynette M., primary, Lele, Subodh M., primary, Sasson, Aaron R., primary, Guha, Sushovan, primary, Mallya, Kavita, primary, Anderson, Judy M., primary, Hollingsworth, Michael A., primary, and Batra, Surinder K., primary

Published
2023
Full Text
View/download PDF

21. Supplementary Fig. 1 from MUC4-Mediated Regulation of Acute Phase Protein Lipocalin 2 through HER2/AKT/NF-κB Signaling in Pancreatic Cancer

Author

Kaur, Sukhwinder, primary, Sharma, Neil, primary, Krishn, Shiv Ram, primary, Lakshmanan, Imay, primary, Rachagani, Satyanarayana, primary, Baine, Michael J., primary, Smith, Lynette M., primary, Lele, Subodh M., primary, Sasson, Aaron R., primary, Guha, Sushovan, primary, Mallya, Kavita, primary, Anderson, Judy M., primary, Hollingsworth, Michael A., primary, and Batra, Surinder K., primary

Published
2023
Full Text
View/download PDF

38. Systemic Immune-Inflammatory Index Association with Survival in Patients Undergoing Trimodality Therapy for Lung Cancer.

Author

Coutu, Brendan G., Johnson, Kurtis C., Bhirud, Abhi, Baine, Michael J., Zhen, Weining, Zhang, Chi, Trujillo, Karin P., and Bennion, Nathan R.

Subjects
LUNG cancer prognosis, LUNG cancer treatment, BIOMARKERS, LUNG cancer, INFLAMMATION, REGRESSION analysis, ADJUVANT treatment of cancer, CHEMORADIOTHERAPY, NEUTROPHILS, LYMPHOCYTES, PLATELET count, CHI-squared test, KAPLAN-Meier estimator, SURVIVAL analysis (Biometry), DESCRIPTIVE statistics, COMBINED modality therapy, PROGRESSION-free survival
Abstract

Purpose: The systemic immune-inflammation index (SII) is correlated with patient survival in various solid malignancies including non-small-cell lung cancer (NSCLC). However, limited information is available on the prognostic implication of the SII in patients undergoing trimodality therapy for stage III NSCLC. Methods: At our institution, 81 patients underwent curative intent trimodality therapy (neoadjuvant chemoradiotherapy followed by surgical resection) for stage III NSCLC from 2004 to 2019. The SII was calculated at the time of diagnosis as platelet count × neutrophil count/lymphocyte count. χ2 analysis was used to compare categorical variables. A Kaplan-Meier analysis was performed to estimate disease-free survival (DFS), overall survival (OS), and freedom from recurrence (FFR) rates, with Cox regression used to determine absolute hazards. Results: Patients underwent neoadjuvant radiation therapy to a median dose of 4,500 cGy concurrent with a median of 3 cycles of chemotherapy (most commonly carboplatin and paclitaxel) followed by surgical resection (86.4% lobectomy and 13.6% pneumonectomy) with mediastinal lymph node dissection. At a median follow-up of 68.4 months, a low SII (<1,260) at diagnosis was independently associated with an improved OS (hazard ratio [HR]: 0.448, p = 0.004), DFS (HR: 0.366, p < 0.001), and FFR (HR: 0.325, p = 0.002). Conclusions: We identified that a low SII was associated with improved OS, DFS, and FFR in patients undergoing trimodality therapy for stage III NSCLC. The interplay of the immune system and lung cancer outcomes remains an active area of investigation for which further study is warranted. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

46. Diffuse lesions secondary to sarcoidosis mimicking widespread metastatic breast cancer: A case report.

Author

Vieira, Heidi, Neilsen, Beth K., Sleightholm, Richard, Hankins, Jordan, Freifeld, Alison, Moore, Gerald, Wahl, Andrew, and Baine, Michael J.

Subjects
METASTATIC breast cancer, DIAGNOSTIC imaging, DIFFERENTIAL diagnosis, SARCOIDOSIS
Abstract

This case of sarcoidosis mimicking metastatic breast cancer serves as a reminder of the need to consider differential diagnoses even when the clinical scenario and imaging findings are highly suggestive of metastases. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results